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Abstract
Neurocognitive impairment is being increasingly
recognized as an important issue in patients with
cancer who develop cognitive difficulties either as
part of direct or indirect involvement of the nervous
system or as a consequence of either chemotherapy-
related or radiotherapy-related complications. Brain
radiotherapy in particular can lead to significant
cognitive defects. Neurocognitive decline adversely
affects quality of life, meaningful employment, and
even simple daily activities. Neuroprotection may be a
viable and realistic goal in preventing neurocognitive
sequelae in these patients, especially in the setting of
cranial irradiation. Lithium is an agent that has been
in use for psychiatric disorders for decades, but
recently there has been emerging evidence that it
can have a neuroprotective effect.
This review discusses neurocognitive impairment in
patients with cancer and the potential for
investigating the use of lithium as a neuroprotectant
in such patients.
Introduction
Cognitive changes are a documented consequence of can-
cer therapies, including chemotherapy and radiotherapy.
Indeed, the ability to inhibit cell division, the key element
in cancer therapies, causes reduction in neurogenesis,
which is implicated in mood and cognitive disorders.
Lithium is a mood stabilizer with known neuroprotective
activity, a characteristic that is thought to underpin its
therapeutic efficacy. In this review, we discuss preclinical
and clinical studies investigating the possibility that
lithium can ameliorate the neurocognitive deterioration
seen in patients undergoing cancer treatment such as cra-
nial irradiation and chemotherapy.
The progress made in controlling systemic cancer is
often hampered by relapse in the central nervous system
(CNS). Systemic therapies, including both cytotoxic and
biologic agents, do not achieve the same concentration in
the CNS because of the blood-brain barrier. Conse-
quently, there is a lower success rate for disease control
in the CNS compared with extracranial areas. Metastatic
and most primary brain tumors carry a dismal prognosis.
Brain metastases are a devastating complication of can-
cer, and have been designated as an area of unmet need
by the US Food and Drug Administration.
Radiotherapy is delivered to the brain for the palliative
treatment of primary brain tumors and brain metastases,
and also for treatment to prophylactically decrease the
occurrence of CNS relapse in selected patients in diseases
such as small cell lung cancer (SCLC) and certain hemato-
logical malignancies with known high rates of CNS relapse.
Brain radiotherapy can lead to cognitive impairment and
mood symptoms, which can further decrease quality of life
in patients with limited expected survival. Chemotherapy
drugs, such as doxorubicin, are similarly associated with
cognitive side effects [1,2]. Patients who achieve long-term
remission may struggle to return to normal life and func-
tioning because of cognitive impairment.
Neurocognitive impairment in patients with cancer
In broad terms, brain tumor treatment is multimodal, with
surgery, radiotherapy, and chemotherapy being involved.
All three treatments may affect the neurocognitive out-
comes [3]. In addition to its use in patients with cancer
involving the CNS, brain radiotherapy is also used as pro-
phylaxis in patients with limited stage SCLC who achieve
good extracranial disease control.
Chemotherapy and neurocognition
‘Chemo brain’ has been studied in women with breast
cancer, and also in other malignancies such as colon and
non-small cell lung cancer (NSCLC). These studies seem
to show a decline (sometimes transient) in cognitive
function, after chemotherapy or haemopoietic stem-cell
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transplantation, particularly executive functions and
short-term memory [4,5]. Using functional neuroimaging,
abnormal activity of the frontal cortex, cerebellum, and
basal ganglia has been shown in breast-cancer survivors
as long as 5 to 10 years after chemotherapy [6]. Some
studies with follow-up periods of more than 20 years
show that women with breast cancer perform worse, on
average, than random population controls on neuropsy-
chological tests [7]. However, some patients may perform
less well than controls even before chemotherapy. It is
not known whether a component of the pre-treatment
cognitive changes is paraneoplastic. Neuropsychological
training may improve cognitive performance,[8] and
pharmacologic intervention with agents such as modafi-
nil may also be helpful [9].
Acute cognitive change induced by specific chemother-
apy drugs is rare, with the exception of ifosfamide, which
causes encephalopathy in approximately 12% of patients
[10]. The delirium usually resolves within a few days.
High-dose methotrexate may cause delirium with ence-
phalopathy several days after the infusion, which lasts for
a few days [11]. Indeed, methotrexate, whether given
intravenously or intrathecally, is one of the few che-
motherapeutic agents that cause significant cognitive
dysfunction.
Radiation and neurocognition
Radiation mediates neurocognitive effects by affecting
glial cells, neural stem and progenitor cells [12,13], and
the vascular structures [14,15]. Cranial irradiation deliv-
ered to mice has been shown to reduce neural prolifera-
tion, translating to long-term reduction in neurogenesis
[16,17]. Reduction in neurogenesis is documented as a
core component of the pathophysiology of depression
and dementia, and many treatments for depression may
promote neurogenesis[18]. Stress that can precipitate
mood disorders can additionally produce neuronal atro-
phy and reduction of neurogenesis [19].
Radiotherapy is a significant factor in the neurocogni-
tive decline of patients with cancer with brain metastases.
Chronic changes in cognitive function not preceded by
delirium can result from brain radiation, sometimes
enhanced by chemotherapy, particularly with methotrex-
ate [3].This is particularly evident in long-term survivors
of radiosensitive malignancies, such as CNS lymphomas
and some cases of SCLC.
Brain radiotherapy is commonly used as a palliative
treatment for patients with brain metastases, but also in
diseases with a relatively good prognosis, such as medul-
loblastoma, ependymoma, germinoma, and acute lym-
phoblastic leukemia. As mentioned above, prophylactic
cranial irradiation is also used in certain clinical situa-
tions, such as with limited-disease SCLC and good extra-
cranial response to therapy.
Acute encephalopathy may result from radiation with
fractions of 300 cGy or more to a large CNS treatment
field. This can result in, or contribute to, other causes of
delirium. Patients who have large tumors with increased
intracranial pressure, and who are irradiated with high
doses per fraction, may develop acute encephalopathy
and even brain herniation after the initial few treatments
[20]. Although there are no data from studies on this,
corticosteroids are used in practice either to prevent or
ameliorate symptoms.
Somnolence syndrome is a common intermediate side
effect of cranial radiotherapy, which occurs approximately
6 weeks after treatment, and manifests as lethargy,
increased sleepiness, poor attention or subtle memory
changes, and altered temperament [21]. Somnolence syn-
drome occurs in approximately 60% of children treated
with cranial irradiation for acute lymphatic leukemia, and
in up to 80% of adults who are treated with cranial irradia-
tion for brain tumors [22]. Somnolence syndrome usually
occurs approximately 6 weeks after treatment, and mani-
fests as lethargy, increased sleepiness, and poor attention
or memory. There have been some reports of an asso-
ciated fever [23]. In adults, the condition tends to be
subtler, with memory changes and altered temperament. It
is self-limiting, and does not seem to be linked to later
sequelae. It is thought to be due to acute demyelination
affecting neural signal transmission. Large doses of dexa-
methasone given during radiotherapy has been suggested
to ameliorate this, but this is not routine practice [23].
Neurocognitive complications of cranial radiation are
among the most distressing symptoms for patients,
families, and care providers. In children who have cra-
niospinal irradiation for medulloblastoma or germinoma,
or more focal radiation for tumors such as ependymo-
mas, gliomas, or craniopharyngiomas, the late effects are
marked. Commonly, there is a decline in intelligence
quotient (IQ) (full-scale, verbal and nonverbal domains),
which tends to be more marked in patients who have a
younger age at treatment; larger volumes of brain irra-
diated, particularly the temporal lobes; higher premorbid
IQ; hydrocephalus requiring a shunt; and intrathecal che-
motherapy in addition to radiotherapy. Children often
have an initial improvement after the completion of ther-
apy, but a later decline occurs 12 to 24 months later [4].
The decline clearly affects school completion and voca-
tional achievements in later life. In older children,
impaired short-term memory, processing speed, and
shortened concentration span are common, and these
problems progress with age.
The desire to reduce neurocognitive complications has
driven many recent studies. Historically, children treated
before the age of 2 years were often institutionalized
because of their iatrogenic impairments. In both adults
and children, dose, brain volume exposed, and fraction
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size are strong determinants of the outcomes. It is now
well known that children receiving brain irradiation
experience less severe neuropsychologic toxicity when
treated with 23.4 Gy, rather than 36 Gy cranial irradia-
tion, and that older children are less likely to develop
cognitive impairment than children who are younger at
the time of irradiation, suggesting greater vulnerability
of the developing brain [24].
The use of cranial irradiation is linked to problems
with long-term memory and concentration [15]. Modern
radiotherapy techniques allow for sparing of sensitive
areas of the CNS. Techniques such as intensity-modu-
lated radiation therapy (IMRT) allow sparing of crucial
structures such the optic chiasm or the pituitary gland.
Sparing of the hippocampus, which has a crucial role in
short-term memory, can also be achieved with the use
of IMRT. This approach can still deliver acceptable tar-
get coverage and homogeneous delivery to the tumor
area in the case of brain metastases [25]. Obviously,
short-term memory is only one of the cognitive aspects
affected by hippocampal damage. Exposure of other
parts of the brain, such as the frontal and prefrontal
cortex, may have a more subtle effect. Declines in atten-
tion, executive function, and motor, language, and gen-
eral intellectual skills have been reported. Therefore,
prospective well-controlled studies are needed to vali-
date the role of hippocampal sparing. This question is
currently under investigation in a randomized controlled
phase II cooperative group trial to test the hypothesized
neurocognitive benefit.
Additionally, there is a suggestion of a more rapid
progression of dementing illness in patients receiving
cranial irradiation, although the number of long-term
survivors is limited [15]. There is also a risk of increased
frequency of cerebrovascular accidents and small-vessel
disease, thought to be due to intimal thickening of the
cerebral arteries. Other late changes that can occur are
the development of small cavernomas within the white
matter, which may occasionally cause a low-pressure
bleed, of little clinical significance.
Depression is another significant problem in this set-
ting, and may be linked to reduction in neurogenesis.
Indeed, it is possible to block the efficacy of antidepres-
sants in some, but not all, models of antidepressant effi-
cacy by impeding neurogenesis using cranial radiation
[26]. This suggests that there are neurogenesis-depen-
dent and neurogenesis-independent mechanisms of anti-
depressant action.
Lithium and neurocognitive dysfunction
Lithium is a standard part of the management of mod-
erate to severe bipolar disorder and schizoaffective dis-
orders, with a well-understood toxicity profile [27-29].
Preclinical data on the neuroprotective effect of lithium (3)
Lithium exerts neuroprotective effects and is associated
with less cognitive loss in various brain-injury models,
including after cranial irradiation [30,31]. In addition,
neural stem/progenitor cells positively respond to lithium
treatment under basal conditions [32,33]. In addition to
evidence from animal studies, neuroimaging research in
humans supports the observation that lithium exerts neu-
roprotective effects. One study used three-dimensional
magnetic resonance imaging and brain segmentation to
evaluate increases in the effect of lithium on grey-matter
volume in patients with bipolar mood disorder. The use of
4 weeks of lithium treatment was shown to increase brain
grey-matter content [34] and hippocampal volume [35].
The authors concluded that increases in grey matter prob-
ably occurred as a result of neurotrophic effects.
Lithium was found to protect irradiated hippocampal
neurons in mice from apoptosis, resulting in better perfor-
mance in learning and memory function [31]. Lithium is
known to reduce oxidative stress, specifically via the glu-
tathione system [36]. In bipolar disorder, lithium has been
shown to prevent the loss of cortical grey matter that
occurs as part of the neuroprogressive cascade in the dis-
order [37].
Whole-brain irradiation delivered to mice has been
shown to reduce neural proliferation in the dentate gyrus
subgranular zone, translating to long-term reduction in
neurogenesis [38]. The number of neurons in the brain is
controlled by production of new neurons and neuronal
death. Glutamate, glucocorticoids, and haloperidol reduce
neural progenitor proliferation in cerebellar granule cells
[39], whereas lithium prevents the loss of proliferation
induced by these agents. Microangiopathic and capillary
loss in the treated areas, compounded by intimal thicken-
ing in the larger vessels, leads to reduction in vascularity
and in white-matter damage [40,41].
Neural progenitor proliferation in the developing and
adult brain plays a prominent role in the production of
new neurons. One of the main targets of radiation to
treat the observed neurocognitive effects seems to be
the glial cells [42]. Oligodendrocyte loss in particular
seems to affect the development of myelination of the
damaged nerves [43]. Other major targets are neural
stem and progenitor cells and the vascular structures
[42]. Lithium increases the recovery of proliferating
neural stem and progenitor cells in the dentate gyrus,
and reduces the incidence of radiation-induced gliosis.
In addition, neural stem and progenitor cells respond
positively to lithium treatment under basal conditions
[32] and in brain-injury models [33].
Lithium-induced neural progenitor proliferation in
vitro suggests that similar effects might occur in vivo, and
this action could also be related to its clinical efficacy
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[39]. In animal studies, the effect of lithium treatment is
partly mediated by inhibiting inflammation and by pro-
moting proliferation and survival of neural stem and pro-
genitor cells [44]. Lithium was shown to increase
progenitor, rather than stem-cell, proliferation in both
non-ischemic and ischemic rat brains [44].
The nt/b-Catenin pathway regulates cell-fate decisions
during development in vertebrates and invertebrates.
Glycogen synthase kinase (GSK)-3 has been shown to be
an essential mediator of neural progenitors during brain
development. The Wnt ligand is a secreted glycoprotein
that binds to receptors, leading to displacement of the
multifunctional kinase GSK-3b from the the adenoma-
tous poliposis coli protein (APC)/axin/GSK-3b complex.
In the absence of Wnt-signal (off-state), b-catenin, an
integral cell-cell adhesion adaptor protein and transcrip-
tional co-regulator, is targeted for degradation by the
APC/axin/GSK-3b-complex [45]. Lithium is an activator
of b-catenin signaling, and may overcome inhibition of
b-catenin signaling [46]. Lithium may also exert some of
its neuroprotective actions via inhibition of GSK-3b [47].
Bcl-2 and Bax are apoptosis-related genes. Lithium
induces a decrease in Bax protein levels and causes an
increase in the Bcl-2/Bax ratio [48]. Long-term lithium
treatment suppresses p53 and Bax expression, but
increases Bcl-2 expression [48]. Activation of WNT sig-
naling by lithium chloride, which inhibits the negative
regulator of the WNT/b-catenin pathway (GSK3b),
reduces astrocytic activation in neurodegenerative dis-
eases, and is thought to do so through its ability to
induce WNT signaling [46]. The neurotransmitter dopa-
mine can exert its effects by acting on a lithium-sensitive
signaling cascade involving Akt/PKB and GSK-3 [49]. In
mouse striatum, lack of the dopamine transporter results
in inactivation of Akt and concomitant activation of
GSK-3a and GSK-3b, but these changes are effectively
reversed by lithium [49]. Lithium additionally seems to
block the excitotoxicity that is mediated by increased
levels of intracellular calcium [50]. This is a pathway to
apoptosis, [51-53] mediated by glutamate, and is a repli-
cated finding in mood and cognitive disorders [54].
The Morris water maze (MWM) is a test of spatial
learning for rodents, in which the rodents rely on distal
cues to navigate from start locations around the peri-
meter of an open swimming arena to locate a submerged
escape platform [55]. Lithium was found to protect irra-
diated hippocampal neurons in mice from apoptosis,
resulting in better performance of rats in the MWM,
reflecting better learning and memory function.
Clinical data on the potential neuroprotective effect
of lithium
There are limited prospective clinical data on the use of
lithium as a neuroprotectant. Several small imaging
studies have shown that patients with bipolar disorder
treated with long-term lithium therapy have fewer struc-
tural changes on brain imaging compared with patients
with bipolar disorder of at least 2 years in duration who
received lithium for less than 3 months. Patients with
bipolar disorder who were not treated with lithium were
found to have smaller left hippocampal volumes than
controls (corrected P<0.05). The study included 17
patients with bipolar disorder who had at least 2 years
of lithium therapy, compared with 12 patients with
bipolar disorder who had less than 3 months of lifetime
lithium exposure. The group treated with lithium had
hippocampal volumes similar to those of 11 healthy
controls and of young, lithium-naïve patients [56]. In a
similar study, measurement of left prefrontal N-acetyl
aspartate (NAA) levels was performed using magnetic
resonance spectroscopy at 1.5 T. The study included 27
participants treated with lithium, 16 participants not
treated with lithium (<3 months exposure) and 21
healthy controls. The non-lithium group had lower pre-
frontal NAA levels than the lithium-treated group
(P<0.01) or control group (P<0.05) [57].
In a large observational cohort study in Denmark,
Kessing and colleagues showed that patients taking
lithium were more likely than the general population to
develop dementia; however, for those who continued to
take lithium, the rates fell to those of the general popu-
lation [58]. It is unclear whether this reflects drug
effects, or is a proxy of disease-related effects, as people
with mood disorders are at increased risk of developing
dementia compared with the general population. This
effect was not seen in the population taking anticonvul-
sants. A follow-up study published by the same group in
2010 showed that continued treatment with lithium was
associated with a reduced rate of dementia in patients
with bipolar disorder, in contrast to continued treatment
with other drugs such as anticonvulsants, antidepres-
sants, or antipsychotics [59]. A meta-analysis of lithium
on cognitive performance found minor negative effects
on cognition [60].
Long-term lithium treatment was also investigated in
amnestic mild cognitive impairment as part of a study that
randomized 45 participants to receive lithium (0.25 to 0.5
mmol/l) (n = 24) or placebo (n = 21) in a double-blind
trial [61]. Lithium treatment was associated with a signifi-
cant decrease in CSF concentrations of P-tau (P = 0.03).
Tau proteins are proteins that stabilize microtubules.
When tau proteins are defective, and no longer stabilize
microtubules properly, they can result in dementias. The
study reported better performance on the cognitive sub-
scale of the Alzheimer’s Disease Assessment Scale and in
attention tasks [61].
In an open-label study, the effects of administering
lithium carbonate to patients with Alzheimer’s disease
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for up to 1 year were evaluated [62]. No cognitive bene-
fits were found in the patients who completed the study.
In a different placebo-controlled, single-blind study,
lithium was used to treat patients with mild Alzheimer’s
disease for 10 weeks. Lithium treatment was not found to
have significant benefits on either cognitive performance
or CSF concentrations of disease-related biomarkers [63].
There has been one early-phase study in which lithium
was used as a neuroprotectant, which was presented in
abstract form at the 2007 American Society for Therapeu-
tic Radiology and Oncology [64], and updated at the 2008
annual meeting of the Society of Neuro-Oncology [65].
Conclusions
Neuroprotection may be a viable and realistic goal in pre-
venting neurocognitive sequelae in patients with cancer,
especially in the setting of cranial irradiation. There are
two types of pathological processes amenable to interven-
tion that could be targeted: 1) normal physiological pro-
cesses that happen in excess, such as excitotoxicity,
pruning. or excessive apoptotic activity [48] and 2) failure
of trophic processes, such as reduced neurogenesis, senes-
cence of progenitor cell generation, and differentiation.
Such an approach would involve regulating the processes
of growth and regeneration, and the rescue of brain cells
that may be at risk of damage or even death [66].
Lithium is an agent that has been in use for psychiatric
disorders for decades, providing us with a wealth of
experience with this ‘old’ medication that has the potential
for a novel indication. Nevertheless, there remain many
unanswered questions. Because lithium may reduce free
radical damage, which is one of the primary mechanisms
of action for radiotherapy, it may reduce the efficacy of
radiotherapy. There is also a theoretical concern that if the
neural proliferating cells are stimulated during radiation
treatment, this may actually increase the neural damage by
reducing the repopulation pool.
In many studies of the biochemical and behavioral mod-
els, not only has lithium been found to be neuroprotective,
but also antidepressants, atypical antipsychotics, and many
substances such as vitamin A. However, none has shown a
significant effect size in subsequent adequately powered
human clinical trials for this indication. To date, there is
no evidence that a pharmacological intervention could
prevent or reduce radiation-induced somnolence syn-
drome or late neurocognitive impairment. In palliative
patients, whose median survival may be measured in
weeks, a significant proportion of survival time is affected
by somnolence syndrome. Neurocognitive decline
adversely affects quality of life, meaningful employment.
and even simple daily activities [67,68]. Lithium has shown
promise in preliminary studies, but if its benefit as a neu-
roprotectant in patients receiving cancer treatment is
confirmed, it may ultimately lead to improvement in the
quality of life for these patients.
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